帕金森病中震管理策略:优化患者护理
Nicola Pavese1,2, David Ledingham1,2
1Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK.
Neurodegenerative disease management
|August 17, 2025
概括
帕金森病的震是一种主要的运动症状,通常抵抗标准治疗. 这篇评论探讨了震类型,神经化学和先进的管理策略,包括DBS和聚焦超声波.
科学领域:
- 神经学 神经学
- 运动障碍 运动障碍
背景情况:
- 震是帕金森病 (PD) 的一个主要运动症状.
- 帕金森发往往对多巴胺类疗法具有耐火性,与布拉迪基尼西亚和刚性不同.
- 这种折射性表明了不同的潜在神经化学机制.
研究的目的:
- 为了审查帕金森病中的类型.
- 讨论帕金森的神经化学和潜在的治疗目标.
- 探索PD震的当前和新兴管理策略.
主要方法:
- 关于帕金森病的文献评论.
- 对震的神经化学基础的分析.
- 药物,手术和非药物治疗的概述.
主要成果:
- 帕金森发对治疗的反应各不相同,表明有不同的机制.
- 神经成像和可穿戴设备显示出改善震评估的希望.
- 像深度大脑刺激和聚焦超声波这样的先进疗法为耐火性震提供了替代方案.
结论:
- 了解PD震的神经化学是开发向治疗的关键.
- 结合药理,手术和非药理策略的多模式方法对于有效的震管理至关重要.
- 技术进步正在提高帕金森病的诊断和管理.
相关概念视频
01:24Parkinson's Disease: Treatment
380
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
380
01:15Parkinson's Disease: Overview
704
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
704
01:28Drug Therapy
98
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
98
01:20Myasthenia Gravis: Overview and Treatment
1.9K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.9K
01:25Dysrhythmias VII: Nursing Management of Dysrhythmias
107
Nursing management of dysrhythmias involves the following:AssessmentSubjective Assessment:The initial step involves gathering patient-reported symptoms such as dizziness, palpitations, and chest discomfort. It is crucial to collect a detailed history, including previous heart conditions, current medication use, and lifestyle factors like caffeine and alcohol consumption.Objective Assessment:This involves observing clinical signs such as jugular venous distention, cool and pale skin, and...
107
01:22Alzheimer's Disease: Treatment
261
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
261